Ultragenyx Pharmaceutical Inc.
RAREFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Ultragenyx Pharmaceutical Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 14 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 15, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| ARIZONA STATE RETIREMENT SYSTEM | 2026-03-31 | 23,850 | $500K | SEC filing |
| Allworth Financial LP | 2026-03-31 | 2,035 | $42.6K | SEC filing |
| TWINBEECH CAPITAL LP | 2026-03-31 | 16,954 | $355K | SEC filing |
| Caption Management, LLC | 2026-03-31 | 110,000 | $2.3M | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 3,295 | $69K | SEC filing |
| BIT Capital GmbH | 2026-03-31 | 18,000 | $377K | SEC filing |
| Creative Planning | 2026-03-31 | 32,435 | $680K | SEC filing |
| PUBLIC EMPLOYEES RETIREMENT SYSTEM OF OHIO | 2026-03-31 | 26,832 | $562K | SEC filing |
| GAMMA Investing LLC | 2026-03-31 | 769 | $16.1K | SEC filing |
| Squarepoint Ops LLC | 2026-03-31 | 444,539 | $9.31M | SEC filing |
| Summit Trail Advisors, LLC | 2026-03-31 | 16,640 | $349K | SEC filing |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2026-03-31 | 804,109 | Not shown | SEC filing |
| Parkman Healthcare Partners LLC | 2026-03-31 | 235,000 | $4.92M | SEC filing |
| Knott David M Jr | 2026-03-31 | 33,069 | $693K | SEC filing |
| Neo Ivy Capital Management | 2026-03-31 | 73,601 | $1.54M | SEC filing |
| JPMORGAN CHASE & CO | 2026-03-31 | 245,928 | $4.75M | SEC filing |
| Assenagon Asset Management S.A. | 2026-03-31 | 2,257,671 | $47.3M | SEC filing |
| Aberdeen Group plc | 2026-03-31 | 38,499 | $807K | SEC filing |
| BNP PARIBAS FINANCIAL MARKETS | 2026-03-31 | 490,783 | $10.3M | SEC filing |
| Qube Research & Technologies Ltd | 2026-03-31 | 914,760 | $19.2M | SEC filing |
- Each value is checked against Ultragenyx Pharmaceutical Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Ultragenyx Pharmaceutical Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Ultragenyx Pharmaceutical Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-02 · KAKKIS EMIL D: Larger than 77 of the 78 other insider sales of Common Stock on file. SEC filing
- 2025-03-03 · KAKKIS EMIL D: Larger than all 78 other insider sales of Common Stock on file. SEC filing
- 2025-02-28 · KAKKIS EMIL D: Larger than 72 of the 78 other insider sales of Common Stock on file. SEC filing
- 2024-02-07 · KAKKIS EMIL D: Larger than 73 of the 78 other insider sales of Common Stock on file. SEC filing
- 2023-12-29 · KAKKIS EMIL D: Larger than 73 of the 78 other insider sales of Common Stock on file. SEC filing
- 2023-10-23 · Kassberg Thomas Richard: Larger than 75 of the 78 other insider sales of Common Stock on file. SEC filing
- 2023-10-19 · KAKKIS EMIL D: Larger than 76 of the 78 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-15 | Parschauer Karah Herdman · EVP and Chief Legal Officer | Common Stock | S — Open market or private sale | −1,899 | 24.62 | SEC filing |
| 2026-06-15 | Sanders Corazon (Corsee) D. · Director | Common Stock | S — Open market or private sale | −2,000 | 25.05 | SEC filing |
| 2026-06-01 | Horn Howard · Chief Financial Officer | Common Stock | S — Open market or private sale | −4,653 | 23.77 | SEC filing |
| 2026-05-18 | SULIMAN SHEHNAAZ · Director | Common Stock | S — Open market or private sale | −5,740 | 25.12 | SEC filing |
| 2026-05-05 | Crombez Eric · EVP and Chief Medical Officer | Common Stock | S — Open market or private sale | −344 | 24.96 | SEC filing |
| 2026-05-01 | Horn Howard · Chief Financial Officer | Common Stock | S — Open market or private sale | −4,683 | 24.90 | SEC filing |
| 2026-04-01 | Horn Howard · Chief Financial Officer | Common Stock | S — Open market or private sale | −4,683 | 20.97 | SEC filing |
| 2026-03-10 | Parschauer Karah Herdman · EVP and Chief Legal Officer | Common Stock | S — Open market or private sale | −3,508 | 22.67 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-05-14 | Fust Matthew K · Director | Common Stock | A — Grant, award, or other acquisition | +7,751 | SEC filing |
| 2026-05-14 | SULIMAN SHEHNAAZ · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +14,058 | SEC filing |
| 2026-05-14 | NARACHI MICHAEL · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +14,058 | SEC filing |
| 2026-05-14 | WELCH DANIEL G · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +14,058 | SEC filing |
| 2026-05-14 | Sanders Corazon (Corsee) D. · Director | Common Stock | A — Grant, award, or other acquisition | +7,751 | SEC filing |
| 2026-05-14 | WELCH DANIEL G · Director | Common Stock | A — Grant, award, or other acquisition | +7,751 | SEC filing |
| 2026-05-14 | Dunsire Deborah · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +14,058 | SEC filing |
| 2026-05-14 | NARACHI MICHAEL · Director | Common Stock | A — Grant, award, or other acquisition | +7,751 | SEC filing |
Showing 8 of 32 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2023-06-07 | Fust Matthew K · Director | Common Stock | D — Disposition to the issuer | −3,300 | SEC filing |
| 2023-04-16 | Huizenga Theodore Alan · SVP, Chief Accounting Officer | Common Stock | D — Disposition to the issuer | −181 | SEC filing |
| 2023-03-01 | Pinion John Richard · See Remarks | Common Stock | D — Disposition to the issuer | −4,014 | SEC filing |
| 2023-03-01 | Kassberg Thomas Richard · CBO & EVP | Common Stock | D — Disposition to the issuer | −3,394 | SEC filing |
Showing 4 of 4 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.